Latest & greatest articles for alendronate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alendronate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alendronate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alendronate

1. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. (PubMed)

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis).ACTIVExtend, an extension of ACTIVE, enrolled patients who completed 18 months of ABL-SC or PBO in ACTIVE to receive up to 24

Full Text available with Trip Pro

2017 Mayo Clinic Proceedings

2. Treatment of osteoporosis after alendronate or risedronate. (PubMed)

Treatment of osteoporosis after alendronate or risedronate. Alendronate (ALN) and risedronate (RIS) are ideal as first-choice therapy options in the treatment of postmenopausal osteoporosis. What to do for patients who do not respond adequately to bisphosphonates has not been conclusively determined, but transitioning to other therapies should be considered. The aim of this article is to describe potential alternatives for patients switching from ALN or RIS to other therapies for osteoporosis

2015 Osteoporosis International

3. ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. (PubMed)

ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO).Women who completed ABL or PBO treatment in ACTIVE were eligible to receive up to 24 months of ALN. We evaluated the incidence of vertebral and nonvertebral fractures and changes in bone

Full Text available with Trip Pro

2018 Journal of Clinical Endocrinology and Metabolism

4. Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency

Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 24 June 2016 EMA/354096/2016 EMEA/H/C/004172 Questions and answers (...) Withdrawal of the marketing authorisation application for Alendronic Acid/Colecalciferol Mylan (alendronic acid and colecalciferol) On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency. What is Alendronic Acid/Colecalciferol Mylan? Alendronic Acid

2016 European Medicines Agency - EPARs

5. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. (PubMed)

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. The MOTION (Monthly Oral Therapy with Ibandronate for Osteoporosis Intervention) study reported that once-monthly ibandronate was noninferior to once-weekly alendronate in terms of increasing bone mineral density (BMD) at the lumbar spine and total hip over 12 months (...) . On analysis of secondary and exploratory end points in MOTION, which included trochanter and femoral neck BMD, monthly ibandronate was found to be noninferior to weekly alendronate. The coprimary, secondary, and exploratory BMD end points from MOTION have been previously reported.This report presents additional results from the MOTION study, including response rates in terms of lumbar spine and total hip BMD gains above baseline; findings from a comparison of serum concentrations of bone turnover markers

2009 Clinical therapeutics

6. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. (PubMed)

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption.We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate (...) femoral fractures were adjudicated.Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P

Full Text available with Trip Pro

2017 NEJM

7. A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis

A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01128257 Recruitment Status : Completed First Posted : May 21, 2010 Last Update

2010 Clinical Trials

8. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. (PubMed)

Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC). Once-weekly alendronate improves bone mass and is well tolerated in these patients, but there is a concern because of poor compliance. Therefore, the efficacy, adherence, and safety of monthly ibandronate (150 mg) with weekly alendronate (70 mg) were compared (...) in the alendronate group, completed the trial. At 2 years both treatments resulted in a significant increase in BMD at the lumbar spine (from 0.875 ± 0.025 to 0.913 ± 0.026 g/cm(2), P < 0.001 with alendronate, and from 0.898 ± 0.024 to 0.949 ± 0.027 g/cm(2), P < 0.001 with ibandronate). The mean percentage change was 4.5% and 5.7%, respectively (P = not significant). BMD increased at the total hip by 2.0% and 1.2%, respectively. Changes in bone markers were similar in both groups and one patient with alendronate

Full Text available with Trip Pro

2013 Hepatology

9. Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday

Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday UTCAT3257, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Patients Being Treated with Oral Alendronate and in Need of a Dental Implant May Reduce the Risk of Osteonecrosis of the Jaw by Taking a Drug Holiday Clinical Question In patients being treated with oral (...) alendronate and wanting a dental implant, does taking a drug holiday decrease the likelihood of developing osteonecrosis of the jaw? Clinical Bottom Line Patients being treated with oral alendronate and in need of a dental implant should have their dentist discuss the discontinuation of their oral bisphosphonate with their prescribing physician before continuing with dentoalveolar surgical treatment. The amount of risk reduction seems to necessitate further investigation and therefore, one cannot provide

2017 UTHSCSA Dental School CAT Library

10. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. (PubMed)

Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. Bisphosphonates are the first-line medications for treating osteoporosis. The aim of our prospective study was to compare the efficacy of zoledronate with that of alendronate in women with post-menopausal osteoporosis based on the evaluations of bone mineral density (BMD) and serum levels of biochemical markers (...) of bone remodelling.Chinese women with post-menopausal osteoporosis were randomly assigned to the zoledronate (n = 52) or alendronate (n = 53) group, and were treated with 5 mg zoledronate intravenously once per year and 70 mg alendronate orally once per week, respectively. During a 3-year follow-up period, the lumbar spine, femoral neck and total hip were examined using dual-energy x-ray absorptiometry every 12 months to assess BMD, and the serum levels of amino-terminal propeptide of type I

2016 Journal of clinical pharmacy and therapeutics

11. Comparing the effect of Glucosamine and Glucosamine With Alendronate in Symptomatic Relieve of Degenerative Knee Joint Disease: A Double- blind Randomized Clinical Trial Study. (PubMed)

Comparing the effect of Glucosamine and Glucosamine With Alendronate in Symptomatic Relieve of Degenerative Knee Joint Disease: A Double- blind Randomized Clinical Trial Study. Degenerative Joint Disease (DJD) is the most common joint disease in human beings. Previous studies have explained that glucosamine is preferred as placebo and in efficacy compared with NSAID's in treatment of patients' knee osteoarthritis. Alendronate was used to treat osteoporotic patients and its efficacy (...) was established.The aim of this study was to compare the efficacy of administration of glucosamine alone and its combination with alendronate in osteoarthritis of the knee.The study included 130 patients with osteoarthritis who randomly received glucosamine alone (group II) (500mg TDS), or combination of glucosamine (500mg TDS) and alendronate (70mg weekly) (group I) for 12 weeks. Patients were evaluated on 1, 3, 6 and 12 weeks after beginning the treatment to evaluate efficacy of each treatment.Statistically

Full Text available with Trip Pro

2012 Jundishapur journal of natural pharmaceutical products

12. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis

The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of risedronate compared with generic alendronate for the treatment of postmenopausal women with osteoporosis. The authors concluded that risedronate

Full Text available with Trip Pro

2010 NHS Economic Evaluation Database.

13. Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy

Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy (BILANZ) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean

2012 Clinical Trials

14. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. (PubMed)

Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. No data on the pharmacological treatment of normocalcemic hyperparathyroidism (NPHPT) are available. We treated 30 NPHPT postmenopausal women with alendronate/cholecalciferol (treated group) or vitamin D alone (control group). Over 1 year, bone mineral density (BMD) increased significantly in treated group, but not in control group. Both treatments did not affect serum or urinary (...) calcium.Normocalcemic primary hyperparathyroidism (NPHPT) is defined by normal serum calcium and consistently elevated PTH levels after ruling out the causes of secondary hyperparathyroidism. It is likely that subjects with NPHPT may develop kidney and bone disease. As no data on the pharmacological treatment of NPHPT are available, we aimed to investigate the effects of alendronate and cholecalciferol on both BMD and bone biochemical markers in postmenopausal women with NPHPT. Safety of vitamin D was evaluated

2015 Osteoporosis International

15. First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates. (PubMed)

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates. The aim of the following study is to evaluate adherence and compliance of postmenopausal osteoporotic patients for different regimens of bisphosphonates (BP).A prospective observational randomized comparative 1 year study was undertaken to evaluate the adherence/compliance (...) rates of most commonly prescribed daily alendronate (ALN), weekly risedronate (RIS) and monthly ibandronate (IBN) BP regimens.Nearly 40% was the 1 year adherence rate with BP and 41.33% of non-compliance. Whereas, 8.66% was interrupted compliance rate and 6% switched over to other anti-osteoporotic treatment. The three treatment arm did not vary significantly. However, numerically maximum adherence rate of 56% was recorded in monthly BP regimen followed by weekly (36%) and daily regimen (32

Full Text available with Trip Pro

2014 Journal of mid-life health

16. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. (PubMed)

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. High-dose corticosteroids, used for many medical conditions, are associated with rapid bone loss from sites such as the vertebrae, and compression fractures can be observed within months. Recent trials suggest treatment with bisphosphonates or active vitamin D analogs can reduce bone loss and the risk of fracture associated with glucocorticoids (...) , but few studies have directly compared such agents. We conducted a randomized, multicenter, open-label trial to compare the efficacy of alendronate, calcitriol, and simple vitamin D in prevention and treatment of glucocorticoid-induced bone loss. A total of 195 subjects (134 females and 61 males) commencing or already taking glucocorticoids were randomized to one of three groups: calcitriol, 0.5 to 0.75 microg/day; simple vitamin D (ergocalciferol, 30,000 IU weekly) plus calcium carbonate (600 mg

Full Text available with Trip Pro

2003 Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

17. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. (PubMed)

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Oral ibandronate 150 mg is the first bisphosphonate approved for once-monthly treatment of postmenopausal osteoporosis. To investigate whether once-monthly ibandronate 150 mg increases lumbar spine and total hip bone mineral density (BMD) to the same degree as weekly alendronate 70 mg.This was a 12-month, randomised, multinational, multicentre, double (...) -blind, double-dummy, parallel-group, non-inferiority trial, conducted in 65 centres in North America, Latin America, Europe and South Africa. The study included postmenopausal women, mean lumbar spine (L2-L4) BMD T-score < -2.5 and > or = -5.0. Patients received either ibandronate 150 mg once monthly or alendronate 70 mg once weekly.Co-primary efficacy endpoints were 12-month change (%) from baseline in mean lumbar spine and total hip BMD. Changes (%) from baseline in trochanter and femoral neck BMD

2008 Current medical research and opinion

18. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment

Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study investigated the effect of various generic alendronate costs on the cost-effectiveness of osteoporosis screening and treatment in women aged 65 years and older. The authors concluded that osteoporosis screening followed by alendronate treatment provided value-for-money across a wide range of alendronate costs compared with no screening

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

19. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis Liu H, Michaud K, Nayak S, Karpf D B, Owens D K, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three treatment strategies for postmenopausal women with severe osteoporosis: usual care (UC) based on calcium or vitamin D plus 5 years of alendronate therapy (alendronate alone); UC plus 2 years of teriparatide therapy (teriparatide alone); and UC plus 2 years of teriparatide therapy followed

Full Text available with Trip Pro

2006 NHS Economic Evaluation Database.

20. [Use of alendronate in osteoporosis: is it cost-effective?]

[Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Kristiansen I S, Falch J A, Andersen L, Aursnes I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate in the treatment of osteoporosis. Type of intervention Treatment, primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Women with a bone mass density (BMD) less than 2.5 standard deviations below maximum BMD (the WHO

1997 NHS Economic Evaluation Database.